Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple blood test guide steroid use in COPD emergencies?

NCT ID NCT04234360

Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether giving steroids to people hospitalized for a COPD flare-up works better when their blood shows high levels of eosinophils (a type of white blood cell). Researchers compared treatment failure rates between those who got steroids and those who got a placebo. The trial was stopped early, but it aimed to find out if eosinophil levels can predict who benefits most from steroids.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

182 people

The number who actually took part.

Started

Oct 2021

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients admitted to a participating hospital (ward, ICU or emergency services) for an acute COPD exacerbation * For patients with known COPD: COPD defined according to GOLD 2018 criteria: (1) Post-bronchodilator FEV1/FVC \< 70% of predicted values; (2) \> 10 pack years smoking history * For incident COPD cases with no spirometric history: symptoms and exposure according to GOLD 2018 report will be considered for the diagnosis, but if the spirometric diagnosis is not confirmed during follow-up, then the patient will be excluded * Signed consent has been obtained, or the appropriate emergency procedure (under French law) allows enrolment * Subjects must be covered by public health insurance * Patient available for 3 months of follow-up. Subjects must be able to attend all scheduled visits and to comply with all trial procedures. Exclusion Criteria: * Subject unable to read or write; language barrier * Subject who is in a dependency or employment with the sponsor or investigator * Pregnancy or lactation * Patients who are prisoners or under other forms of judicial protection * Patients under any kind of guardianship * The patient has already participated in the present protocol * The patient is participating in another interventional study or has done so in the past 3 months * The patient is in an exclusion period determined by a previous study * The patient has been taking long-term systemic corticosteroids for longer than 1 month prior to inclusion * The patient has already received \> 1 mg/kg of systemic corticotherapy in the past 48h * Intubated-ventilated patient * Administration of oral experimental drug is impossible * Cancer within the last 12 months * Current diagnosis of Asthma * T2-inflammation targeting biologics (Benralizumab, reslizumab, mepolizumab, dupilumab) treatment * Admitted for any other reason including, but not limited to, pulmonary embolism, pneumothorax, heart failure * Known allergy to corticosteroids * Consideration of a potential negative drug interaction with corticosteroids (at the investigator's discretion) * White blood cell formula already performed and distributed to implicated teams * Directives for limitation-of-care ("LATA" in French) already established * SARS-Cov2 positive test carry out during the COPD exacerbation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD exacerbation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD exacerbation

Contacts and locations

Locations

  • APHM - Hôpital Nord

    Marseille, France

  • APHP - Hopital Européen Georges Pompidou

    Paris, France

  • APHP - Hôpital BICHAT

    Paris, France

  • APHP - Hôpital Cochin

    Paris, France

  • APHP - Hôpital Universitaire Pitié-Salpétrière

    Paris, France

  • CH Libourne

    Libourne, France

  • CHRU Strasbourg

    Strasbourg, France

  • CHU Amiens

    Amiens, France

  • CHU Bordeaux - Hôpital Haut Lévêque

    Pessac, France

  • CHU Brest - Hôpital Caval Blanche

    Brest, France

  • CHU Montpellier

    Montpellier, France

  • CHU Nancy

    Nancy, France

  • CHU Nîmes

    Nîmes, France

  • CHU Reims

    Reims, France

  • Clinique du Parc

    Castelnau-le-Lez, France

  • Hospice Civils de Lyon

    Lyon, France

  • Hôpital Larrey CHU Toulouse

    Toulouse, France

  • Hôpital Nord Franche-Comté

    Trévenans, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.